DaVita shares what happened during its earnings call for the third quarter of 2026.

Oct 29, 2026, 8:00 PM ETResultsRead the original at Benzinga

Neutral

DaVita reported progress in kidney care and treatment volume, but higher technology costs and more missed treatments than expected weigh against it. The report does not show a clear overall change in its business outlook.

DVA · DaVita Inc.

AI read · Neutral

The AI's read

The call shows progress in DaVita’s kidney-care business, treatment volume, and patient care. Its 2026 operating income forecast for that business rose to at least $65 million. But technology costs ran higher than expected and missed treatments exceeded expectations. The new dialyzers are not expected to bring financial benefits until the second half of 2028. These mixed details do not show a clear overall change in DaVita’s business outlook.

Get alerts for DVA

Follow DaVita Inc. (DVA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for DVA

Free on the App Store and Google Play, or on the web.